Helpdesk

Sales contact

Home > Resources > How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

31 March 2022

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Download the infographic

Ask for more information

Learn more:

Subscribe to our newsletter

Rare disease clinical research: it is time to tackle what...

The client’s voice: why they consistently choose Kayentis

Why you should join Kayentis

Rethinking pediatric clinical trials: guidelines from pediatric experts

Overcoming challenges in long-lasting pediatric clinical trials – Insights from...

Tackling the specificities of NASH/MASH clinical trials

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

SCOPE 2025

FEB 3-6 2025 • Orlando, USA

Booth #931 https://www.scopesummit.com/

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA